{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:30:26Z","timestamp":1786505426489,"version":"build-2736575974"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100011723","name":"Myeloma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>There is an ongoing need for accessible combination therapies for patients with relapsed\u2010refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T\u2010cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open\u2010label phase 2 trial. The planned sample size was 250 patients but recruitment was stopped early due to changes in standard of care. Between 2016 and 2018, 104 RRMM patients from 26 UK hospitals were recruited and randomized to receive cyclophosphamide, pomalidomide, and dexamethasone (CPd) or pomalidomide and dexamethasone (Pd) using minimization. Fifty\u2010four participants in each arm were analysed. The primary end\u2010point, progression\u2010free survival (PFS) was not met with median 6.9\u2009months (95% Confidence Interval\u00a0(CI): 5.7\u201310.4) for CPd versus 4.6\u2009months for Pd (95% CI: 3.5\u20137.4), although not significant; reflecting underpowering from early closure. CPd showed a higher overall response rate, and toxicity was comparable to previously reported Pd regimens. Peripheral blood T\u2010cell analysis revealed stronger and more sustained enrichment of CD3+ T cells, HLA\u2010DR\u2010positive CD8+ and CD8+ effector memory cells in the CPd arm. Pretreatment CD4+ T\u2010cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T\u2010cell composition.<\/jats:p>","DOI":"10.1111\/bjh.70611","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:07:16Z","timestamp":1781597236000},"page":"557-568","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and immunological effects of adding cyclophosphamide to pomalidomide\u2013dexamethasone in relapsed\u2010refractory multiple myeloma: The randomized\n                    <scp>MUKseven<\/scp>\n                    trial"],"prefix":"10.1111","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-571X","authenticated-orcid":false,"given":"Andrew","family":"Hall","sequence":"first","affiliation":[{"name":"Clinical Trials Research Unit Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Croft","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"},{"name":"The Royal Marsden Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Walker","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Boyd","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadie","family":"Roberts","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Holroyd","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3560-0132","authenticated-orcid":false,"given":"Mamta","family":"Garg","sequence":"additional","affiliation":[{"name":"Leicester Royal Infirmary  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Ferris","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"},{"name":"National Institute for Health and Care Research Leeds Biomedical Research Centre  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Pierceall","sequence":"additional","affiliation":[{"name":"Translational Development and Diagnostics Celgene Corporation  Summit New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[{"name":"Translational Development and Diagnostics Celgene Corporation  Summit New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Translational Development and Diagnostics Celgene Corporation  Summit New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"},{"name":"The Royal Marsden Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"},{"name":"The Royal Marsden Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00119"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-682518"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.02.004"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03649-3"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0245-1"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.11.012"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0124"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01356-z"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3333"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022823"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011225"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.048496"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37420-0"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5506"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101571"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70611","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:10:08Z","timestamp":1786504208000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/bjh.70611"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70611","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2025-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}